About
Nobelpharma was founded in 2003, and in 2008 we obtained our first marketing approval for an ethical drug, NOBELZIN®. We now have marketing approvals for and sell 18 new drugs and one new medical device. In the pharmaceuticals industry, there are no companies of similar scale and age launching as many new drugs as we have. It is the pursuit of our unique product planning and research and development that has led to this achievement. We engage in the projects of "drugs and medical devices for unmet medical needs" which are critical but neglected. We chose not to carry out the time-consuming and costly basic researches. Instead, we conduct license negotiations and research activities focusing on patient needs and select the best possible candidates (new drug candidates) from outside our company. This is because we want to deliver the drugs and medical devices for unmet medical needs to the medical front as quickly as possible, for the benefit of the patients. Unique management strategy
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 2 investors are based in Shinkawa, Tokyo, Japan.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Shinkawa, Japan
Contact Information
Find more investors like Nobelpharma
Search Investors